TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05996445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb662
Description: Intravenous (IV) administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb662
Description: Intravenous (IV) administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keytruda® (pembrolizumab)
Description: Intravenous (IV) administration
Study: NCT05627986

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05647122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9592
Description: Varying doses of AZD9592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9592
Description: Varying doses of AZD9592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9592
Description: Varying doses of AZD9592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion
Study: NCT06406478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schedule Change
Description: This 4-day workweek is defined by any 4 ten hour shifts between Sunday and Saturday. It will be up to the discretion of participants in the intervention group to coordinate which 4 days they work. The 4 days will most likely be weekdays, but some participants may work weekends. If participants do any work from home, they will clock in remotely to account for the time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Schedule Change
Description: The control group will continue to work five days per week, receiving standard practice for the schedule policies at the participating study sites.
Study: NCT06780813

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental oxygen therapy
Description: In this grou participants will receive supplemental oxygen in the form of a Venturi mask upon low oxygen saturation in oximetry (SaO2\<95%) and a nasal oxygen mask in all other cases during the first 2 postoperative days
Study: NCT05630053

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cementless Persona Knee System
Description: The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Persona Knee System
Description: The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
Study: NCT04605263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN-PPN DBS Surgery
Description: Subject will undergo standard bilateral STN DBS surgery and have 2 additional leads placed in the same burr with bilateral PPN targets

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation Surgery (DBS)
Description: DBS lead implantation of bilateral STN
Study: NCT05121493

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Poor Plasma Tear Drops
Description: Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet free fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of white blood cells (WBC), red blood cells (RBC), and platelets when compared to the concentration before processing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Tear Drops
Description: Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of WBC and RBC and 100 x 10³ μl or ≥ 50% recovery of platelets when compared to the pre-platelet count.
Study: NCT06294548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat
Description: Valemetostat is an inhibitor of the enzymes enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat
Description: Valemetostat is an inhibitor of the enzymes enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is commercially available. Atezolizumab combined with bevacizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is commercially available. Atezolizumab combined with bevacizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is commercially available. Bevacizumab combined with atezolizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is commercially available. Bevacizumab combined with atezolizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.
Study: NCT04934943

Intervention type: DIAGNOSTIC_TEST
Intervention: mini_FC
Description: 100 ml of Crystalloids infused over 1 minute - data recording and new baseline - FC 4 ml/kg in 10 minutes - data recording
Study: NCT05370885

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: VE202
Description: VE202 is a rationally defined, live biotherapeutic product for oral administration.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: VE202
Description: VE202 is a rationally defined, live biotherapeutic product for oral administration.

Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin Oral Capsule
Description: Vancomycin is an antibiotic used to treat or prevent infection

Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin Oral Capsule
Description: Vancomycin is an antibiotic used to treat or prevent infection

Intervention type: OTHER
Group type: OTHER
Intervention: VE202 Placebo
Description: VE202 Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: VE202 Placebo
Description: VE202 Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Vancomycin Placebo
Description: Vancomycin Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Vancomycin Placebo
Description: Vancomycin Placebo
Study: NCT05783986

Intervention type: OTHER
Intervention: randomly divided
Description: 500 patients of our hospital were randomly divided into testing group and internal validation group, and 100 patients in collabrative hospital were external validation group.

Intervention type: OTHER
Intervention: randomly divided
Description: 500 patients of our hospital were randomly divided into testing group and internal validation group, and 100 patients in collabrative hospital were external validation group.
Study: NCT05929755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Medrol
Description: steroid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gel-Flow NT
Description: hemostatic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gel-Flow NT
Description: hemostatic agent
Study: NCT05497700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Bolus injection of 6 mg ephedrine to keep mean arterial blood pressure above 65 mm Hg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Bolus injection of either 6 mcg norepinephrine to keep mean arterial blood pressure above 65 mm Hg
Study: NCT05769543

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WATSU application
Description: 20-minute application of WATSU

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lecture
Description: 20-minute lecture on WATSU technique
Study: NCT05672082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714
Description: Participant received one injection of 200 MBq of \[18F\]DPA-714
Study: NCT05978648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: 240 mg/m2, intravenous drip over 30 min within 4 hours before chemotherapy administration on the same day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: 240 mg/m2, intravenous drip over 30 min within 4 hours before chemotherapy administration on the same day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m2, intravenous drip, d1, Q3W, 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, intravenous drip, d1, Q3W, 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2, intravenous drip, d1,8,15, Q3W, 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2, intravenous drip, d1, Q3W, 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: area under curve(AUC) = 6, intravenous drip, d1, Q3W, 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg in Cycle 1, 6 mg/kg in subsequent cycles, intravenous drip, d1, Q3W, for 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840mg in Cycle 1, 420mg in subsequent cycles, intravenous drip, d1, Q3W, for 1 year.
Study: NCT06018597

Intervention type: DRUG
Intervention: Sevoflurane Baxter, 100%, Inhalation Vapour, Liquid 250 mL
Description: No procedure was performed on the patient other than routine anesthesia management.We compared sevoflurane consumption amount in the patient undergoing general anesthesia with sevoflurane according to their metabolic age.

Intervention type: DRUG
Intervention: Sevoflurane Baxter, 100%, Inhalation Vapour, Liquid 250 mL
Description: No procedure was performed on the patient other than routine anesthesia management.We compared sevoflurane consumption amount in the patient undergoing general anesthesia with sevoflurane according to their metabolic age.

Intervention type: DRUG
Intervention: Sevoflurane Baxter, 100%, Inhalation Vapour, Liquid 250 mL
Description: No procedure was performed on the patient other than routine anesthesia management.We compared sevoflurane consumption amount in the patient undergoing general anesthesia with sevoflurane according to their metabolic age.
Study: NCT04847479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 self-test
Description: Up to 3 COVID-19 self-test kits will be given to individuals who have tested positive for COVID-19. Participants will be instructed to give test kits to close contacts who have been exposed to them.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 test referral
Description: Text messages with testing information will be given to individuals who have tested positive for COVID-19. Participants will be instructed to share text messages with close contacts who have been exposed to them.
Study: NCT06780995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power Exercise for Stroke Recovery (POWER)
Description: POWER incorporates 3 progressive phases: Phase 1 Familiarization (Week 1) as a low-intensity version of the training program to acclimate participants to the movements (body weight resisted or light weights, RPE 2-3 Fairly light to Moderate). Phase 2 Strength (Weeks 2-5) progresses loads to achieve volitional fatigue within 6-8 repetitions (RPE 7-9 Very hard to Very very hard). Phase 3 Power (Weeks 6-10) will use intensities RPE 4-6 (Somewhat hard to Very hard), and exercises will be executed at the highest possible velocity to focus on muscle power. The Power phase is intentionally designed with exercises to emphasize functional movements such as fast sit to stands, lunging and calf raises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training Engaging Guidelines to Enhance Total Health (STRENGTH)
Description: STRENGTH is based on current clinical practice guidelines for RET after stroke. It will include the same Familiarization week as the POWER program (Week 1), followed by progressive conventional RET involving 3 sets of 10-15 repetitions at moderate to high intensities (RPE 4-5 Somewhat hard to Hard) (Weeks 2-10). The external resistance will be progressed to maintain this target RPE range. STRENGTH is matched with POWER in length (60-minute sessions over 10 weeks), frequency (3x/week) and format (in-person supervision).
Study: NCT06397547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flipped Learning
Description: Materials for students' pre-class studies and for use by the instructor during class will be created by the researchers. For students in the experimental group to come prepared for class according to the flipped learning model, digital materials will be prepared by the researchers. The experimental group will receive digital materials prior to the topic. The links to these materials will be sent to the students, who can access them via their mobile phones and watch the explanatory and demonstration videos as many times as they wish. Subsequently, the topic will be presented to the students. They will summarize the information learned from the videos and engage in question-answer sessions and discussions using prepared digital resources to address any points they do not understand. To reinforce the practices in the experimental group, online word clouds and quizzes will be sent.
Study: NCT05171647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive SC mosunetuzumab on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-8 (cycle length = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Participants will receive IV polatuzumab vedotin every three weeks (Q3W) for 6 cycles (cycle length = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Participants will receive IV rituximab on Day 1 of each cycle for 8 cycles (cycle length = 14 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants will receive IV gemcitabine on Day 1 of each cycle for 8 cycles (cycle length = 14 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Participants will receive IV oxaliplatin on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
Study: NCT05044611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anhydrous Amiloride Hydrochloride
Description: Amiloride is a blocker of ENaC that is administered patients with various disorders, such as primary or secondary hyperaldosteronism. It does not have the market authorization in the indication of lithium-induced NDI.~Dose : 5 mg Pharmaceutical form: Tablets Daily Posology : 10 mg Route of administration : oral Procedures and duration of treatment: 2 months during the double blinded phase and 10 additional months for the open label phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Route of administration : oral the control arm will receive a placebo twice daily during 2 months
Study: NCT06402604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: See above in arm group descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction training
Description: See above in arm group descriptions.
Study: NCT04871308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Anesthesia is induced using midazolam or etomidate, and sufentanil. A target-controlled infusion of propofol and remifentanil is used for anesthesia maintenance.~From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: During the same time window for dexmedetomidine, normal saline is infused at the same rate calculated for dexmedetomidine.
Study: NCT04862663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Phase Ib: Capivasertib 320 mg/ 400 mg administered PO BD 4 days on /3 days off per week for 4 weeks (28 days cycle) Phase III: : Capivasertib, administered PO BD 4 days on / 3 days off per week for 4 weeks (28 days cycle) at the dose confirmed in the phase Ib portion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Phase Ib: Capivasertib 320 mg/ 400 mg administered PO BD 4 days on /3 days off per week for 4 weeks (28 days cycle) Phase III: : Capivasertib, administered PO BD 4 days on / 3 days off per week for 4 weeks (28 days cycle) at the dose confirmed in the phase Ib portion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
Study: NCT05366582

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscope
Description: After the induction, laryngoscopy will be performed with a Video laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2. Failed intubation will be considered if not achieved within 2 minutes
Study: NCT04816773

Intervention type: DEVICE
Intervention: EVOLUTION® NitrX™
Description: EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
Study: NCT04862663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Phase Ib: 100 mg/ 125 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose of 125 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Phase Ib: 200 mg/ 400 mg/ 600 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose confirmed in the phase 1b portion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Phase Ib: 50 mg/ 100 mg/ 150 mg. Twice daily for 28 consecutive days to comprise a complete 28-day cycle
Study: NCT05144516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: COPE +
Description: Six sixty minute sessions that teaches participants distress and communication coping skills.
Study: NCT05599880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is administered at 1.3mg/m2 iv or sc on each Cycly Day1, Days4, and Days8. Bortezomib is administered every 3 weeks for a total of 3 cycles. Thereafter, follow-up is scheduled for 12 months.
Study: NCT05422222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121/TEZ/D-IVA
Description: Fixed-dose combination for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121/TEZ/D-IVA
Description: Fixed-dose combination for oral administration.
Study: NCT05313256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine epinephrine buffered with sodium bicarbonate
Description: When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine buffered with sodium bicarbonate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine epinephrine
Description: When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine.
Study: NCT04860336

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT05807893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab combined with bevacizumab and first-line chemotherapy
Description: Serplulimab combined with bevacizumab and first-line chemotherapy
Study: NCT06126575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant dihydrochloride
Description: A single oral dose of 200 mg elacestrant (2 x 100 mg tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant dihydrochloride
Description: A single oral dose of 200 mg elacestrant (2 x 100 mg tablets).
Study: NCT05158166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA
Description: This is a long-acting alternative to traditional Botox A treatment.